Symposium on vaccines on 10 and 12 May 2022: the importance of lifelong immunisation, lessons from the COVID-19 pandemic, and future prospects

date: 29/04/2022

The FAMHP and are organising two half-day symposia on vaccines on 10 and 12 May 2022. The first day will focus on the FAMHP and the VACCINES spearhead. This will cover topics such as clinical trials, regulatory activities, pharmacovigilance, and inspections. The second day will focus on effective vaccination, before closely examining the way vaccination campaigns are organised and implemented, vaccine hesitancy, and data collection. You can register now.

The COVID-19 pandemic has highlighted the importance of immunisation in combating infectious diseases. The national competent authorities and the pharmaceutical industry have worked intensively to provide the population with safe and effective vaccines against the coronavirus.

On 10 and 12 May 2022, the FAMHP and are organising a symposium on the various activities being undertaken to not only make vaccines available, but also to encourage their acceptance with a view to protecting public health, our healthcare system and society as a whole.

Practical information
•    Attendance at both half-day sessions is free of charge but registration is required. You must register for each half-day session you wish to attend using the online forms: 10 May and 12 May.
•    Presentations will be given in English.
•    Each symposium will start at 9.00 and end at around 13.10.
•    The symposium will be held at the Pacheco Center, Boulevard Pacheco 13, BRUSSELS.


10 May: From concept to vaccines (organised by the FAMHP)
Focus on the activities of the FAMHP and the VACCINES spearhead, covering topics such as clinical trials, regulatory activities, pharmacovigilance, and inspections.

Time Topic Speaker
09.00-09.15 Registration of attendees and welcome coffee  
09.15-09.30 Welcome Xavier De Cuyper, Chief Executive Officer of the FAMHP
09.30-10.00 COVID-19 vaccine trials performed in Belgium and regulatory perspective  Nele Steens
Head of the Research and Development Division (human use), FAMHP
10.00-10.30 Setting up vaccine clinical trials in a pandemic context: experience from study site Fien De Boever
Clinical Unit Manager CEVAC- UZ Gent
10.30-11.00 Perspective for the future: Vaccinopolis and bioprepardness initiative Pierre Van Damme
Universiteit Antwerpen
11.00-11.30 Pause  
11.30-12.00 European marketing authorization procedure in a pandemic context: challenges and learning Christophe Focke
Cel CP, member CHMP, FAMHP
12.00-12.30 Follow up of vaccine safety and lessons learned Jean-Michel Dogné
Université de Namur
12.30-13.00 Impact of the COVID-19 pandemic on inspection activities Karin Froidbise
Head of the Industry Division, FAMHP
13.00 Conclusies Stéphanie Mali
Coordinator of Vaccines Center of Excellence, FAMHP


12 May: From vaccines to vaccination (organised by
Focus on effective vaccination by examining how regional authorities organise and implement their vaccination campaigns, tackle vaccine hesitancy, and collect data on vaccine uptake.


Time Topic Speaker
09.00-09.30 Registration of attendees and welcome coffee  
09.30-09.45 The importance of Belgium as a pharma valley to ensure effective life course vaccination TBD
09.45-10.25 The benefits of vaccines: getting the message across Dr. Nicolas Dauby
CHU Saint-Pierre


An analysis of the Belgian vaccine landscape Ingrid Maes
11.00-11.30 Pause


11.30-12.20 Introducing new vaccines to the public – Challenges and solutions

Bart Croes
Kabinet Wouter Beke

Julie Therasse
Pharmacist to General COVID-19 delegaton for the Government of Wallonnia

12.20-13.00 Collecting data on vaccination as tool to support decision making Joris Van Loenhout
13.00 Conclusions Hugues Malonne
Director general of the DG PRE authorisation, FAMHP


Based on all these experiences, the symposium will also offer an opportunity to consider future developments. How can we use the expertise of the VACCINES spearhead to strengthen Belgium's position in the development of new vaccines? Can regulatory pathways be altered to optimise the evaluation process? What data do we need to support authorities in their decision-making? In short, what changes are needed to make the lifelong vaccination of Belgian patients as effective as possible?


Last updated on 03/05/2022